On Friday, Shares of BWX Technologies Inc (NYSE:BWXT), lost -1.17% to $25.25.
BWX Technologies stated second quarter 2015 revenues of $357.1 million, a decrease of $5.4 million, or 1.5%, from the second quarter of 2014. GAAP earnings per share from ongoing operations for the second quarter of 2015 were $0.00 contrast to $0.20 in the second quarter of 2014. Adjusted (Non-GAAP) earnings per share from ongoing operations, which excludes a $0.27 per share impact of spin-related and restructuring costs for the quarter, were $0.32 contrast to $0.35 in the second quarter of 2014. Unless stated otherwise, the results of operations discussion comprised of in this release are on a ongoing operations basis and exclude the results of operations from our former Power Generation business, which are comprised of as part of suspended operations in the attached financial statements.
“In the first half of 2015, we accomplished the spin-off of our former Power Generation business, as anticipated, while ongoing to deliver solid operating results. BWXT is now better positioned to attract an investor base specifically suited to our Company’s unique operational and financial characteristics,” said Mr. John A. Fees, Executive Chairman. “Our Nuclear Operations segment continued to deliver strong and stable operating performance in the second quarter. In addition, the Nuclear Energy segment produced significantly improved bookings and backlog this quarter. Looking forward, we have a solid backlog in our Nuclear Operations segment, nearly two times the backlog in Nuclear Energy contrast to the preceding year period, and we see good prospects in all of our business segments to deliver EPS growth in the second half of the year.”
BWX Technologies, Inc. engages in government, commercial nuclear, and technical services businesses. The company operates in three segments: Nuclear Operations Group, Technical Services Group, and Nuclear Energy.
Shares of Nevro Corp (NYSE:NVRO), inclined 5.51% to $52.08, during its last trading session.
Nevro Corp., stated financial results for the three and six months ended June 30, 2015.
Recent Accomplishments & Highlights:
- Achieved revenue of $11.4 million in the second quarter of 2015, an enhance of 52% as stated and 81% on a constant currency basis over the same period of the preceding year
- Received FDA approval for HF10 Spinal Cord Stimulation (SCS) therapy with superiority labeling and commenced U.S. launch
- Accomplished a successful follow-on underwritten public offering resulting in net proceeds to Nevro of about $118 million
- Publication of SENZA-RCT pivotal trial results in Anesthesiology
- SENZA-RCT 18-month results presented at the International Neuromodulation Society (INS) 12th World Congress in Montreal and results selected as the “2015 Best Clinical Abstract” at the International Spine Intervention Society meeting in Las Vegas, Nevada
- Over 4,000 chronic pain patients have benefited from HF10 therapy to date
Nevro Corp., a medical device company, develops and commercializes a neuromodulation platform for the treatment of chronic pain. It offers Senza system, a spinal cord stimulation system that delivers its proprietary HF10 therapy.
Finally, Perrigo Company plc Ordinary Shares (NYSE:PRGO), ended its last trade with 1.05% gain, and closed at $190.21.
Perrigo Company plc (NYSE: PRGO; TASE) declared results for the second calendar quarter ended June 27, 2015.
Perrigo’s Chairman, President and CEO Joseph C. Papa commented, “The team delivered a strong financial performance in the quarter, record quarterly net sales, etc. Our Branded Consumer Healthcare segment, comprised of our recently attained Omega Pharma assets, achieved an impressive $401 million in sales, which comprised of new product sales of $33 million. With Omega in our portfolio, merged new product sales for Perrigo were a record $149 million. The Rx segment grew 10% in the quarter on top of a record performance last year. Notwithstanding a decline in the VMS and animal health categories, we grew adjusted operating income by 18% to a record $160 million in the Consumer Healthcare segment. Since the closing of the Omega Pharma acquisition, we have continued to execute on a major component of our ‘Base Plus Plus Plus’ strategy, with three declared acquisitions, two of which build upon our pan-European platform. Our durable business model and future growth prospects are self-evident as we continue to progress on our stand-alone strategy.”
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
